Faron Pharmaceuticals Secures European Patent For Clevegen Cancer Drug

LONDON (Alliance News) - Faron Pharmaceuticals PLC said Thursday that it has been granted a ...

Alliance News 1 February, 2018 | 10:56AM
Email Form

LONDON (Alliance News) - Faron Pharmaceuticals PLC said Thursday that it has been granted a European patent for its cancer treatment Clevegen.

The clinical stage biopharmaceutical company said that the European Patent Office has granted it a patent for the use of Clever-1 antibodies, the mechanism behind Clevegen, for the treatment of cancer. The decision extends the existing Clevegen patent until 2030.

Faron said it is seeking further intellectual property recognition around Clevegen's mechanism that could extend protection to the end of 2038.

The company plans to initiate clinical phase I and II development in 2018.

The planned initial phase I and II trial will target patients with liver, melanoma, ovarian, and pancreatic cancer as part of an adaptive protocol design, which is currently under review by regulators, with feedback anticipated in 2018.

Clevegen is a novel anti-Clever-1 antibody that causes changes in the immune environment of solid tumours by switching immune suppressive M2 macrophages, a type of white blood cell, to immune active M1 macrophages.

"The grant of this patent serves to protect the innovative mechanism underlying Clevegen, which will be important in realising the potential our second wholly-owned product promises. The target receptor Clever-1 is already patent protected but our wider strategy is to establish a broad portfolio of intellectual property for the company and our pipeline products. We look forward to taking Clevegen into the clinic later this year and providing an in-depth update on its development at our R&D Event in February," Faron Chief Executive Markku Jalkanen said.

Faron shares were up 2.2% at 853.00 pence per share on Thursday morning.

By Toby Woodall; tobywoodall@alliancenews.com

Copyright 2018 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar
Rating
Faron Pharmaceuticals Oy 62.15 GBX 1.89 -
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites